



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/252,384	06/01/1994	C. STEVEN MCDANIEL	5842-00502	3543

62754 7590 12/04/2006

DAFFER MCDANIEL, LLP
P.O. BOX 684908
AUSTIN, TX 78768-4908

EXAMINER

PAK, YONG D

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 12/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT PAPER

20061114

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 571-272-0935. The examiner can normally be reached 6:30 A.M. to 5:00 P.M. Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Yong D. Pak
Patent Examiner 1652

Notice to Comply	Application No. 08/254,384	Applicant(s) C. Steven McDaniel	
	Examiner Pak. Yung D	Art Unit 1652	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Sequence Listing does not contain SEQ ID NO:3, most recent Sequence Listing is attached.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



RACT-00100.ST25
SEQUENCE LISTING

<110> Reactive Surfaces, Ltd.
McDaniel, Steven
Rauschel, Frank M.
Wild, James R

<120> Recombinant Organophosphorous Acid Anhydrase and Methods of Use

<130> TAMK145

<140> US 08/252,384
<141> 1994-06-01

<150> US 07/928,540
<151> 1992-08-13

<150> US 07/344,258
<151> 1989-04-27

<160> 2

<170> PatentIn version 3.3

<210> 1
<211> 1337
<212> DNA
<213> Pseudomonas diminuta

<220>
<221> CDS
<222> (63)..(1160)

<400> 1
ctgcagcctg actcggcacc agtcgctgca agcagagtcg taagcaatcg caaggggggca 60
gc atg caa acg aga agg gtt gtg ctc aag tct gcg gcc gcc gca gga 107
Met Gln Thr Arg Arg Val Val Leu Lys Ser Ala Ala Ala Ala Gly
1 5 10 15
act ctg ctc ggc ggc ctg gct ggg tgc gcg agc gtg gct gga tcg atc 155
Thr Leu Leu Gly Gly Leu Ala Gly Cys Ala Ser Val Ala Gly Ser Ile
20 25 30
ggc aca ggc gat cgg atc aat acc gtg cgc ggt cct atc aca atc tct 203
Gly Thr Gly Asp Arg Ile Asn Thr Val Arg Gly Pro Ile Thr Ile Ser.
35 40 45
gaa gcg ggt ttc aca ctg act cac gag cac atc tgc ggc agc tcg gca 251
Glu Ala Gly Phe Thr Leu Thr His Glu His Ile Cys Gly Ser Ser Ala
50 55 60
gga ttc ttg cgt gct tgg cca gag ttc ttc ggt agc cgc aaa gct cta 299
Gly Phe Leu Arg Ala Trp Pro Glu Phe Phe Gly Ser Arg Lys Ala Leu
65 70 75
gcg gaa aag gct gtg aga gga ttg cgc cgc gcc aga gcg gct ggc gtg 347
Ala Glu Lys Ala Val Arg Gly Leu Arg Arg Ala Arg Ala Ala Gly Val
80 85 90 95
cga acg att gtc gat gtg tcg act ttc gat atc ggt cgc gac gtc agt 395
Arg Thr Ile Val Asp Val Ser Thr Phe Asp Ile Gly Arg Asp Val Ser

RACT-00100.ST25

100	105	110			
tta ttg gcc gag gtt tcg cgg gct gcc gac gtt cat atc gtg gcg gcg Leu Leu Ala Glu Val Ser Arg Ala Ala Asp Val His Ile Val Ala Ala	115	120	125	443	
acc ggc ttg tgg ttc gac ccg cca ctt tcg atg cga ttg agg agt gta Thr Gly Leu Trp Phe Asp Pro Pro Leu Ser Met Arg Leu Arg Ser Val	130	135	140	491	
gag gaa ctc aca cag ttc ttc ctg cgt gag att caa tat ggc atc gaa Glu Glu Leu Thr Gln Phe Phe Leu Arg Glu Ile Gln Tyr Gly Ile Glu	145	150	155	539	
gac acc gga att agg gcg ggc att atc aag gtc gcg acc aca ggc aag Asp Thr Gly Ile Arg Ala Gly Ile Ile Lys Val Ala Thr Thr Gly Lys	160	165	170	175	587
gcg acc ccc ttt cag gag tta gtg tta aag gcg gcc gcc cgg gcc agc Ala Thr Pro Phe Gln Glu Leu Val Leu Lys Ala Ala Ala Arg Ala Ser	180		185	190	635
ttg gcc acc ggt gtt ccg gta acc act cac acg gca gca agt cag cgc Leu Ala Thr Gly Val Pro Val Thr Thr His Thr Ala Ala Ser Gln Arg	195		200	205	683
gat ggt gag cag cag gcc gcc att ttt gag tcc gaa ggc ttg agc ccc Asp Gly Glu Gln Gln Ala Ala Ile Phe Glu Ser Glu Gly Leu Ser Pro	210		215	220	731
tca cgg gtt tgt att ggt cac agc gat gat act gac gat ttg agc tat Ser Arg Val Cys Ile Gly His Ser Asp Asp Thr Asp Leu Ser Tyr	225	230	235		779
ctc acc gcc ctc gct gcg cgc gga tac ctc atc ggt cta gac cac atc Leu Thr Ala Leu Ala Ala Arg Gly Tyr Leu Ile Gly Leu Asp His Ile	240	245	250	255	827
ccg cac agt gcg att ggt cta gaa gat aat gcg agt gca tca gcc ctc Pro His Ser Ala Ile Gly Leu Glu Asp Asn Ala Ser Ala Ser Ala Leu	260		265	270	875
ctg ggc atc cgt tcg tgg caa aca cgg gct ctc ttg atc aag gcg ctc Leu Gly Ile Arg Ser Trp Gln Thr Arg Ala Leu Leu Ile Lys Ala Leu	275		280	285	923
atc gac caa ggc tac atg aaa caa atc ctc gtt tcg aat gac tgg ctg Ile Asp Gln Gly Tyr Met Lys Gln Ile Leu Val Ser Asn Asp Trp Leu	290	295	300		971
ttc ggg ttt tcg agc tat gtc acc aac atc atg gac gtg atg gat cgc Phe Gly Phe Ser Ser Tyr Val Thr Asn Ile Met Asp Val Met Asp Arg	305	310	315		1019
gtg aac ccc gac ggg atg gcc ttc att cca ctg aga gtg atc cca ttc Val Asn Pro Asp Gly Met Ala Phe Ile Pro Leu Arg Val Ile Pro Phe	320	325	330	335	1067
cta cga gag aag ggc gtc cca cag gaa acg ctg gca ggc atc act gtg Leu Arg Glu Lys Gly Val Pro Gln Glu Thr Leu Ala Gly Ile Thr Val	340		345	350	1115
act aac ccg gcg cgg ttc ttg tca ccg acc ttg cgg gcg tca tga					1160

RACT-00100.ST25

Thr Asn Pro Ala Arg Phe Leu Ser Pro Thr Leu Arg Ala Ser
355 365

cgccatctgg atccttccag ccagcggcca ctattccccg tcaagatacc gaacgatgaa 1220
gtcgcgcatac gatcgatagg catcttcaat ttgatcaggg ctgccacctc caaagccgtg 1280
gccaccctg tcgatagtct tgaggacgta gggcacaccg tgcttttcga actgcag 1337

<210> 2
<211> 365
<212> PRT
<213> Pseudomonas diminuta

<400> 2

Met Gln Thr Arg Arg Val Val Leu Lys Ser Ala Ala Ala Ala Gly Thr
1 5 10 15

Leu Leu Gly Gly Leu Ala Gly Cys Ala Ser Val Ala Gly Ser Ile Gly
20 25 30

Thr Gly Asp Arg Ile Asn Thr Val Arg Gly Pro Ile Thr Ile Ser Glu
35 40 45

Ala Gly Phe Thr Leu Thr His Glu His Ile Cys Gly Ser Ser Ala Gly
50 55 60

Phe Leu Arg Ala Trp Pro Glu Phe Phe Gly Ser Arg Lys Ala Leu Ala
65 70 75 80

Glu Lys Ala Val Arg Gly Leu Arg Arg Ala Arg Ala Ala Gly Val Arg
85 90 95

Thr Ile Val Asp Val Ser Thr Phe Asp Ile Gly Arg Asp Val Ser Leu
100 105 110

Leu Ala Glu Val Ser Arg Ala Ala Asp Val His Ile Val Ala Ala Thr
115 120 125

Gly Leu Trp Phe Asp Pro Pro Leu Ser Met Arg Leu Arg Ser Val Glu
130 135 140

Glu Leu Thr Gln Phe Phe Leu Arg Glu Ile Gln Tyr Gly Ile Glu Asp
145 150 155 160

Thr Gly Ile Arg Ala Gly Ile Ile Lys Val Ala Thr Thr Gly Lys Ala
165 170 175

Thr Pro Phe Gln Glu Leu Val Leu Lys Ala Ala Ala Arg Ala Ser Leu
180 185 190

RACT-00100.ST25

Ala Thr Gly Val Pro Val Thr Thr His Thr Ala Ala Ser Gln Arg Asp
195 200 205

Gly Glu Gln Gln Ala Ala Ile Phe Glu Ser Glu Gly Leu Ser Pro Ser
210 215 220

Arg Val Cys Ile Gly His Ser Asp Asp Thr Asp Asp Leu Ser Tyr Leu
225 230 235 240

Thr Ala Leu Ala Ala Arg Gly Tyr Leu Ile Gly Leu Asp His Ile Pro
245 250 255

His Ser Ala Ile Gly Leu Glu Asp Asn Ala Ser Ala Ser Ala Leu Leu
260 265 270

Gly Ile Arg Ser Trp Gln Thr Arg Ala Leu Leu Ile Lys Ala Leu Ile
275 280 285

Asp Gln Gly Tyr Met Lys Gln Ile Leu Val Ser Asn Asp Trp Leu Phe
290 295 300

Gly Phe Ser Ser Tyr Val Thr Asn Ile Met Asp Val Met Asp Arg Val
305 310 315 320

Asn Pro Asp Gly Met Ala Phe Ile Pro Leu Arg Val Ile Pro Phe Leu
325 330 335

Arg Glu Lys Gly Val Pro Gln Glu Thr Leu Ala Gly Ile Thr Val Thr
340 345 350

Asn Pro Ala Arg Phe Leu Ser Pro Thr Leu Arg Ala Ser
355 360 365